FGF21-L-Fc融合蛋白表达及其降糖作用初步评价
Expression and pharmacological evaluation of fusion protein FGF21-L-Fc
-
摘要:
成纤维细胞生长因子-21 (FGF21) 是FGF家族成员之一, 最近发现具有独立调节血糖的作用。为了提高FGF21稳定性来达到更好的药效, 通过柔性接头连接, 制备重组融合蛋白FGF21-L-Fc, 并对其生物学活性和体内药效学进行初步研究。纯化后的FGF21-L-Fc融合蛋白经鉴定, 其分子量和特异性均与理论值相符。经微量化的GOD-POD法检测表明, FGF21-L-Fc融合蛋白能刺激体外培养的已分化成熟的3T3-L1脂肪细胞葡萄糖吸收, 其葡萄糖消耗率与野生型相比有很大提高; 在STZ造模糖尿病小鼠体内, 其药效比野生型持续时间长。结果表明, 改造的蛋白比野生型药效更持久, 为以后FGF21的临床应用奠定了基础。
Abstract:FGF21 (fibroblast growth factor 21) is a recently described member of the FGF family. It has been previously demonstrated that FGF21 is a potent regulator of glucose homeostasis. To improve stability of FGF21 for better efficacy, a new form of recombinant FGF21 was generated by fusion of a full length FGF21 gene and the Fc fragment of human IgG4 with flexible linker sequence. To examine the glucose regulation activity of FGF21-L-Fc, 3T3-L1 pre-adipocytes were differentiated into adipocytes, and glucose uptake activity of FGF21-L-Fc was examined by glucose oxidase and peroxidase (GOD-POD) assay. The results showed that in comparison with wild type FGF21, FGF21-L-Fc was more potent in stimulation of glucose uptake by 3T3-L1. In vivo studies on the modified protein demonstrated that FGF-L-Fc had a better efficacy in lowering blood glucose of the STZ-induced diabetic animals and controlled glucose level for a longer time. The results provided a sound basis for further studies.
下载: